DE69018461T2 - Hepatospezifische insulin-analoga. - Google Patents

Hepatospezifische insulin-analoga.

Info

Publication number
DE69018461T2
DE69018461T2 DE69018461T DE69018461T DE69018461T2 DE 69018461 T2 DE69018461 T2 DE 69018461T2 DE 69018461 T DE69018461 T DE 69018461T DE 69018461 T DE69018461 T DE 69018461T DE 69018461 T2 DE69018461 T2 DE 69018461T2
Authority
DE
Germany
Prior art keywords
hepatospecific
insulin analog
insulin analogues
hepatospecific insulin
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69018461T
Other languages
English (en)
Other versions
DE69018461D1 (de
Inventor
Panayotis Katsoyannis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School of Medicine filed Critical Mount Sinai School of Medicine
Publication of DE69018461D1 publication Critical patent/DE69018461D1/de
Application granted granted Critical
Publication of DE69018461T2 publication Critical patent/DE69018461T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
DE69018461T 1989-04-20 1990-04-17 Hepatospezifische insulin-analoga. Expired - Fee Related DE69018461T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34092989A 1989-04-20 1989-04-20
PCT/US1990/002070 WO1990012814A1 (en) 1989-04-20 1990-04-17 Hepatospecific insulin analogues

Publications (2)

Publication Number Publication Date
DE69018461D1 DE69018461D1 (de) 1995-05-11
DE69018461T2 true DE69018461T2 (de) 1995-08-03

Family

ID=23335524

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69018461T Expired - Fee Related DE69018461T2 (de) 1989-04-20 1990-04-17 Hepatospezifische insulin-analoga.

Country Status (15)

Country Link
EP (1) EP0469084B1 (de)
JP (1) JPH04504858A (de)
AT (1) ATE120762T1 (de)
AU (1) AU631868B2 (de)
CA (1) CA2014896A1 (de)
DE (1) DE69018461T2 (de)
FI (1) FI914898A0 (de)
GR (1) GR1000908B (de)
HU (1) HU210142B (de)
IE (1) IE67353B1 (de)
IL (1) IL94163A (de)
NO (1) NO301544B1 (de)
PT (1) PT93832B (de)
WO (1) WO1990012814A1 (de)
ZA (1) ZA902965B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK158390D0 (da) * 1990-07-02 1990-07-02 Novo Nordisk As Nye peptider
DK33591D0 (de) * 1991-02-27 1991-02-27 Novo Nordisk As
US5268453A (en) * 1991-08-08 1993-12-07 Scios Inc. Tissue-selective insulin analogs
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US5888477A (en) 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
US6131567A (en) * 1993-01-29 2000-10-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US5743250A (en) 1993-01-29 1998-04-28 Aradigm Corporation Insulin delivery enhanced by coached breathing
US5915378A (en) * 1993-01-29 1999-06-29 Aradigm Corporation Creating an aerosolized formulation of insulin
US5970973A (en) * 1993-01-29 1999-10-26 Aradigm Corporation Method of delivering insulin lispro
US5873358A (en) * 1993-01-29 1999-02-23 Aradigm Corporation Method of maintaining a diabetic patient's blood glucose level in a desired range
TW404844B (en) * 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
AUPP609198A0 (en) * 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
KR100679878B1 (ko) * 1999-04-26 2007-02-07 아지노모토 가부시키가이샤 멜라노사이트-자극 호르몬 억제제
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP4773354B2 (ja) * 2004-08-18 2011-09-14 株式会社カネカ インスリン結合たんぱく質と結合能力のあるペプチドおよび吸着材
WO2007020256A1 (en) * 2005-08-16 2007-02-22 Novo Nordisk A/S Method for making mature insulin polypeptides
ES2601839T3 (es) 2006-09-22 2017-02-16 Novo Nordisk A/S Análogos de insulina resistentes a proteasas
EP2069502B1 (de) 2006-09-27 2014-02-26 Novo Nordisk A/S Verfahren zur herstellung gereifter insulinpolypeptide
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
MX2010009850A (es) 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
EP2376531A1 (de) * 2008-12-09 2011-10-19 Novo Nordisk A/S Neue insulinanaloga
CA2744558A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
CA2747490C (en) 2008-12-19 2017-02-14 Indiana University Research And Technology Corporation Insulin analogs
EP2582719B1 (de) 2010-06-16 2016-08-10 Indiana University Research and Technology Corporation Einkettige insulinagonisten mit hoher aktivität am insulinrezeptor
JP5912112B2 (ja) 2010-06-24 2016-04-27 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ アミド系インスリンプロドラッグ
BR112014015156A2 (pt) 2011-12-20 2020-10-27 Indiana University Research And Technology Corporation análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira
CN108383902A (zh) 2012-09-26 2018-08-10 印第安纳大学研究及科技有限公司 胰岛素类似物二聚体
KR20150131213A (ko) 2013-03-14 2015-11-24 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 인슐린-인크레틴 접합체들
US9670162B2 (en) 2013-03-14 2017-06-06 The Board Of Trustees Of The Leland Stanford Junio Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof
RS57004B1 (sr) 2013-10-07 2018-05-31 Novo Nordisk As Novi derivat analoga insulina
ES2947409T3 (es) 2014-09-24 2023-08-08 Univ Indiana Res & Tech Corp Profármacos de insulina a base de amida lipídica
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
AU2017378102B2 (en) 2016-12-16 2022-10-13 Novo Nordisk A/S Insulin containing pharmaceutical compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation

Also Published As

Publication number Publication date
ZA902965B (en) 1991-02-27
PT93832A (pt) 1990-11-20
HU903398D0 (en) 1991-12-30
JPH04504858A (ja) 1992-08-27
HU210142B (en) 1995-02-28
ATE120762T1 (de) 1995-04-15
CA2014896A1 (en) 1990-10-20
NO914085L (no) 1991-11-28
HUT59941A (en) 1992-07-28
DE69018461D1 (de) 1995-05-11
FI914898A0 (fi) 1991-10-17
PT93832B (pt) 1996-09-30
AU5541590A (en) 1990-11-16
AU631868B2 (en) 1992-12-10
IE67353B1 (en) 1996-03-20
IE901404L (en) 1990-10-20
NO301544B1 (no) 1997-11-10
IL94163A (en) 1995-08-31
EP0469084A1 (de) 1992-02-05
WO1990012814A1 (en) 1990-11-01
NO914085D0 (no) 1991-10-17
IL94163A0 (en) 1991-01-31
GR1000908B (el) 1993-03-16
GR900100290A (en) 1991-09-27
EP0469084B1 (de) 1995-04-05

Similar Documents

Publication Publication Date Title
DE69018461D1 (de) Hepatospezifische insulin-analoga.
NZ506447A (en) Peptide analogues of insulin with alanine substitutions and pharmaceutical use
ES552093A0 (es) Un procedimiento para sintetizar una secuencia de aminoacidos que contienen la totalidad o parte de la secuencia de aminoacidos de la preprorrelaxina -h2 humana.
NO972264D0 (no) Fremgangsmåter for behandling av multippel sklerose ved bruk av peptidanaloger av human myelin basis protein
DK0538300T3 (da) O-Glycosyleret IFN-alfa
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
IS4510A (is) Peptíð p277 hliðstæður og lyfjasamsetningar sem innihalda þær, til meðhöndlunar eða sjúkdómsgreiningar á sykursýki
PT88086A (pt) Processo para a preparacao de composicoes farmaceuticas a base de sais de alfa-aminoacidos basicos e de alfa-ceto-analogos de aminoacidos de cadeia ramificada apropriadas para o tratamento da uremia
SE7501342L (de)
FI942392A (fi) Peptidejä ja vasta-aineita nivelreuman hoitoon
ATE137487T1 (de) Komplexe, enthaltend s(+)-phenyl-alkansäuren und alpha-hydroxy-alkansäuren
ATE92078T1 (de) Pharmakologisch aktive peptide.
DK0423326T3 (da) Hidtil ukendt fysiologisk aktivt peptid og calcium-metabolisme-regulerende middel, der omfatter peptidet som effektiv besta
DK119391A (da) Humaninsulinanaloger
DE69004051D1 (de) Verwendung eines Polypeptides mit Gammainterferon-Aktivität zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von primitivem Pleura-Krebs.
IT8847737A0 (it) Procedimento per ottenere amminoacidi da sostanze proteiche per uso fertilizzante

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee